Health Care Equipment & Services

Revised Morgan Stanley outlook on CVS Health: stronger pharmacy sales, cost‑control, and stable retail lift earnings, reducing near‑term risk and boosting investor confidence.

EssilorLuxottica’s strategic stake in Armani could boost luxury‑eyewear margins—yet governance disputes risk investor confidence, while careful financing and integration are key.

EssilorLuxottica faces a U.S. lawsuit for allegedly keeping tariff refunds, sparking debate over how big eyewear brands handle government rebates and pricing.

Explore how Stryker’s latest RSU share‑holding adjustments align executive ownership with shareholder value, boosting governance transparency and industry‑wide best practices.

Steris PLC is set to double FY‑2025 earnings, powered by cost cuts, high‑margin AI‑sterilizers, and Asia‑Pacific growth—outpacing rivals while staying ahead of tightening medical‑device rules.

Insulet Corp’s 4% stock dip amid a tech rally still highlights solid fundamentals—score 83, strong earnings outlook, and ETF upside potential.

Medtronic PLC’s new brain‑computer interface partnership with Precision Neuroscience could boost neuromodulation profits by up to 20 % and drive AI‑enabled healthcare growth, offering a data‑driven solution for Parkinson’s and other neurological dis…

CVS Health’s Rule 144 filing: why a block sale could reshape its capital structure, market impact, and competitive strategy—insights investors, regulators, and analysts need to know.

Siemens Healthineers shares dip 3% in a volatile tech sector, but its AI‑radiomics, cardiac MRI cloud and COVID‑PCR breakthroughs signal strong clinical‑market upside.

Abbott Laboratories shows strong device growth, high margins and free‑cash‑flow, yet faces legal risks; investors weigh robust earnings against potential $4‑$6 B liability and value‑based reimbursement trends.